(Suzhou, China, February 20,2025)Suzhou No.4 Pharmaceutical Co., Ltd.reached a strategic cooperation agreement with the well-known South Korean pharmaceutical company SAMOH PHARM Co.,Ltd. in October 2024, formally authorizing SAMOH as the exclusive agent of Diquafosol Sodium in South Korea .This collaboration marks Suzhou No.4 Pharmaceutical Co., Ltd. accelerated efforts to advance its global layout and deepen its coverage in key Asian markets.

Complementary Strengths to Expand the Ophthalmology Treatment Market in South Korea
SAMOH is a benchmark enterprise in South Korea's pharmaceutical field. Leveraging its extensive channel resources and promotional capabilities developed over many years, it has successfully brought multiple innovative therapies to Korean patients. This collaboration will fully utilize SAMOH's terminal network advantages in South Korea, combined with Suzhou No.4 Pharmaceutical Co., Ltd. leading position in the research and production of Diquafosol Sodium. This will accelerate the market entry of the product in South Korea and provide better treatment options for patients with dry eye syndrome.

Executive Perspective
"Collaborating with SAMOH is a significant milestone for us in the Northeast Asia market, "said the chairman of Suzhou No.4 Pharmaceutical Co., Ltd. "The high alignment between both parties in terms of product quality standards and patient service philosophy will facilitate the faster adoption of Diquafosol Sodium within the Korean healthcare system and lay the foundation for future expansion of our cooperation."

About Diquafosol Sodium  
As the first P2Y2 receptor agonist approved globally, Diquafosol Sodium significantly improves symptoms in patients with dry eye syndrome through its innovative mechanism of action. It has obtained clinical validation in multiple countries, including China and Japan. Suzhou No.4 Pharmaceutical Factory owns the complete intellectual property rights of the product and a production system that complies with international GMP standards.